Related references
Note: Only part of the references are listed.Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A. Gronchi et al.
ANNALS OF ONCOLOGY (2012)
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma
Elizabeth Charytonowicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model
Elizabeth G. Demicco et al.
MODERN PATHOLOGY (2012)
Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy
Wei-Lien Wang et al.
CLINICAL SARCOMA RESEARCH (2012)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma
Tiziana Negri et al.
CLINICAL CANCER RESEARCH (2010)
Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors
Roberta Frapolli et al.
CLINICAL CANCER RESEARCH (2010)
Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay
Martin P. Powers et al.
MODERN PATHOLOGY (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Jordi Barretina et al.
NATURE GENETICS (2010)
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
F. Grosso et al.
ANNALS OF ONCOLOGY (2009)
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Claudia Forni et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Role of homologous recombination in trabectedin-induced DNA damage
M. Tavecchio et al.
EUROPEAN JOURNAL OF CANCER (2008)
FUS-DDIT3 Prevents the Development of Adipocytic Precursors in Liposarcoma by Repressing PPARγ and C/EBPα and Activating eIF4E
Pedro A. Perez-Mancera et al.
PLOS ONE (2008)
Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSRI-DDIT3 fusion
B. Bode-Lesniewska et al.
GENES CHROMOSOMES & CANCER (2007)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma
Lisa Licitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Adipocyte differentiation from the inside out
Evan D. Rosen et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma
Nicolo Riggi et al.
CANCER RESEARCH (2006)
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters
M Minuzzo et al.
MOLECULAR PHARMACOLOGY (2005)
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma
AA Sandberg
CANCER GENETICS AND CYTOGENETICS (2004)
Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells - Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis
C Gajate et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Temperature-dependent localization of TLS-CHOP to splicing factor compartments
M Göransson et al.
EXPERIMENTAL CELL RESEARCH (2002)
CCAAT/enhancer-binding proteins: structure, function and regulation
DP Ramji et al.
BIOCHEMICAL JOURNAL (2002)
DNA and its associated processes as targets for cancer therapy
LH Hurley
NATURE REVIEWS CANCER (2002)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
S Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
M Minuzzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice
J Pérez-Losada et al.
ONCOGENE (2000)
Share Paper
